Fig. 2From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinomaThe survival curves of OS and PFS for nimotuzumab group versus non-nimotuzumab group before PSMBack to article page